广东丸美生物技术股份有限公司2025 年半年度报告 公司代码：603983 公司简称：丸美生物 广东丸美生物技术股份有限公司 广东丸美生物技术股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人孙怀庆、主管会计工作负责人王开慧及会计机构负责人（会计主管人员）黄丹 声明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 以实施权益分派股权登记日登记的总股本为基数，向实施权益分派股权登记日登记在册的全 体股东每10股派发现金红利2.50元（含税）。 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的未来计划、发展战略等前瞻性描述不构成公司对投资者的实质承诺，请投 资者注意投资风险。 七、 是否存在被控股股东及其他关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况 否 九、 是 ...

| 持股比 | | 持股 | | 持有有限 | | | 质押、标记或冻结 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东名称 股东性质 | | | | | 售条件的 | | | | | 例(%) | | 数量 | | | | 的股份数量 | | | | | | | | 股份数量 | | | | | | 孙怀庆 境外自然人 | | 72.72 | 291,600,000 | | 0 | 无 | 0 | | | 王晓蒲 境外自然人 | | 8.08 | 32,400,000 | | 0 | 无 | 0 | | | 凯石基金－展麟价值精选 | | | | | | | | | | 未知 | 2.74 | 10,976,601 | | 0 | 未知 | 未知 | | | | 凯石基金飞跃二号单一资 | | | | | | | | | | 产管理计划 | | | | | | | | | | 香港中央结算有限公司 | 未知 | 1.21 | | 4,850,028 | | 0 | 未知 | 未知 | | 交通银行股份有限公司－ | | | | ...

广东丸美生物技术股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 证券代码：603983 证券简称：丸美生物 公告编号：2025-023 二、公司履行的决策程序 （一）董事会会议的召开、审议和表决情况 公司于 2025 年 8 月 21 日召开第五届董事会第七次会议，审议并通过了 2025 年半年度利润分配方案，方案符合公司章程规定的利润分配政策和公司股东回报 规划。 上述事项尚需提交公司 2025 年第一次临时股东大会审议。 （二）监事会意见 重要内容提示： ? 利润分配比例：每10股派发现金红利2.50元（含税）。 ? 本次利润分配以实施权益分派股权登记日登记的总股本为基数，具体日期 将在权益分派实施公告中明确。在实施权益分派的股权登记日前公司总股本发生 变动的，拟维持每股分配比例不变，相应调整每股分配总额，并将在相关公告中 披露。 为积极合理回报投资者、共享企业价值，增强投资者获得感，广东丸美生物 技术股份有限公司（本文简称"公司"）结合经营发展实际情况以及对未来发展 的信心，综合考虑股东利益，制定了2 ...

Meeting Overview - The fifth meeting of the board of directors of Guangdong Marubi Biotechnology Co., Ltd. was held on August 21, 2025, with all 9 directors present [1] - The meeting was convened in compliance with relevant laws and regulations, and the resolutions passed are legally valid [1] Resolutions Passed - All resolutions were approved with 9 votes in favor, 0 against, and 0 abstentions [2][3] - The resolutions included the approval of the 2025 semi-annual report and the special report on the use of raised funds [2] Financial Decisions - The company and its subsidiaries are authorized to apply for a comprehensive credit limit of up to 1.2 billion RMB for various financing activities [3] - A cash dividend of 2.50 RMB (including tax) per 10 shares will be distributed to shareholders based on the total share capital on the record date [3] Upcoming Events - The company will hold its first extraordinary general meeting of 2025 to review the proposed resolutions [4]

公司 2025 年半年度报告及其摘要的编制和审议程序、内容、格式符合中国 证监会和上海证券交易所的有关规定；报告内容真实、客观地反映公司的财务状 况和经营成果；在提出本意见前，未发现参与 2025 年半年度报告编制和审议的 人员有违反保密规定及其他违反法律法规、 《公司章程》或损害公司利益的行为。 证券代码：603983 证券简称：丸美生物 公告编号：2025-019 广东丸美生物技术股份有限公司 关于第五届监事会第六次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、监事会会议召开情况 广东丸美生物技术股份有限公司（以下简称"公司"）第五届监事会第六次 会议于 2025 年 8 月 21 日（星期四）在公司会议室以现场结合通讯方式召开。会 议通知已于 2025 年 8 月 11 日以电子邮件、微信方式发出。本次会议应出席监事 律、法规、部门规章、规范性文件和《公司章程》的规定。 二、监事会会议审议情况 表决情况：3 票同意，0 票反对，0 票弃权。 公司《2025 年半年度募集资金存放与使用情况的专项报 ...

丸美生物8月22日披露半年报，公司上半年实现营业收入17.69亿元，同比增长30.83%；归属于上市公司 股东的净利润1.86亿元，同比增长5.21%；基本每股收益0.46元。公司拟向全体股东每10股派发现金红 利2.5元（含税）。 ...

人民财讯8月22日电，丸美生物（603983）8月22日晚间披露2025年半年报，公司上半年实现营业收入 17.69亿元，同比增长30.83%；归母净利润1.86亿元，同比增长5.21%；基本每股收益0.46元。公司拟每 10股派发现金红利2.5元(含税)。报告期内，营业收入同比增长主要原因系线上渠道持续保持增长。 ...

Financial Performance - The company's operating revenue for the first half of 2025 reached ¥1,769,193,475.01, representing a year-on-year increase of 30.83% compared to ¥1,352,290,860.56 in the same period last year[21]. - The total profit for the first half of 2025 was ¥240,776,293.10, which is a 7.17% increase from ¥224,659,830.54 in the previous year[21]. - The net profit attributable to shareholders of the listed company was ¥185,740,286.43, reflecting a 5.21% increase from ¥176,537,086.78 in the same period last year[21]. - The basic earnings per share for the first half of 2025 was ¥0.46, up 4.55% from ¥0.44 in the same period last year[22]. - The weighted average return on net assets increased to 5.40%, up from 5.19% in the previous year, marking an increase of 0.21 percentage points[22]. Revenue Sources - The increase in operating revenue is primarily attributed to sustained growth in online channels[22]. - The Marubi brand generated 1.250 billion yuan in revenue, up 34.36% year-on-year, while the PL Lianhuo brand reached 516 million yuan, increasing by 23.87%[29]. - The online channel generated revenue of 1.571 billion yuan, accounting for 88.87% of total revenue, with a year-on-year growth of 37.85%[36]. - The offline channel achieved revenue of 197 million yuan, representing 11.13% of total revenue, with a year-on-year decline of 7.07%[36]. Expenses and Costs - Operating costs increased to ¥449,287,741.20, reflecting a growth of 31.21% due to higher sales revenue[47]. - Sales expenses rose to 1 billion yuan, a year-on-year increase of 39.31%, primarily due to rising online traffic costs and ongoing brand building efforts[29]. - Research and development expenses amounted to 40.70 million yuan, reflecting a year-on-year growth of 13.53%[29]. Cash Flow - The net cash flow from operating activities increased by 97.41%, amounting to ¥115,647,247.15 compared to ¥58,582,996.50 in the previous year[21]. - Operating cash inflow for the first half of 2025 reached ¥1,775,691,102.87, a 41.0% increase from ¥1,259,531,556.22 in the first half of 2024[110]. - Cash outflow from investing activities totaled ¥235,365,414.78, compared to ¥483,688,388.40 in the previous year, indicating a reduction of 51.3%[111]. Market Position and Strategy - The company received the "2025 Forbes China Beauty Industry Excellence Brand 100" award, further solidifying its market position[34]. - The company is investing in the "smart cosmetics manufacturing plant" and "marketing upgrade and operations headquarters" projects[50]. - The company faces increasing market competition due to the rapid growth of e-commerce and the entry of foreign brands into the domestic market[56]. Shareholder Information - The company plans to distribute a cash dividend of ¥2.50 per 10 shares (including tax) to shareholders registered on the dividend distribution date[6]. - The company reported a profit distribution of 208,520,000.00 to shareholders, indicating a commitment to returning value to investors[117]. - The total number of ordinary shareholders as of the end of the reporting period is 17,371[88]. Innovation and Development - The company launched the innovative "Super Mask" product, which quickly gained market recognition due to its unique formula and effectiveness[31]. - The company established three new collaborative projects in academic and industrial innovation, expanding its expert pool to 110 members, enhancing innovation capabilities and technical reserves[32]. - In the first half of 2025, the company applied for 25 new patents, bringing the total to 619, with 16 new authorized invention patents, totaling 365 authorized patents[32]. Financial Health and Assets - The company's net assets attributable to shareholders at the end of the reporting period were ¥3,365,535,062.95, a slight decrease of 0.44% from ¥3,380,406,892.85 at the end of the previous year[21]. - Total assets decreased by 5.87% to ¥4,765,479,158.62 from ¥5,062,564,094.81 at the end of the previous year[21]. - The total liabilities and equity structure remains robust, supporting future growth initiatives[96]. Compliance and Governance - The financial report was approved for release on August 21, 2025, indicating timely compliance with regulatory requirements[123]. - The company has confirmed its ability to continue as a going concern for at least 12 months from the reporting date, with no significant issues affecting its operational capacity[125]. - The company will ensure that the IPO prospectus does not contain any false records or significant omissions, and it will assume legal responsibility for its accuracy and completeness[68].

证券代码：603983 证券简称：丸美生物 公告编号：2025-020 广东丸美生物技术股份有限公司 关于2025年第二季度主要经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 根据上海证券交易所《上海证券交易所上市公司自律监管指引第 3 号行业信 息披露：第十三号——化工》的要求，现将公司 2025 年第二季度主要经营数据 披露如下： 二、2025 年第二季度公司主要产品和原材料的价格变动情况 （一）主要产品价格变动情况 眼部类产品平均售价上升原因：主要系本期售价较高的眼霜产品升级销售占 比提升以及售价较低的眼膜产品销售占比下降所致。 美容类产品平均售价上升原因：主要系本期优化了营销策略，减少了低价引 主要产品 产量（支） 销量（支） 营业收入（元） 眼部类 1,417,633 1,293,001 206,219,439 护肤类 4,321,217 4,012,166 364,708,224 洁肤类 1,248,862 1,089,700 65,706,024 美容类 2,942,370 3,173,96 ...

证券代码：603983 证券简称：丸美生物 公告编号：2025-022 广东丸美生物技术股份有限公司 关于使用部分闲置募集资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 广东丸美生物技术股份有限公司（以下简称"公司"或"丸美生物"）于 2025 年 8 月 21 日召开了第五届董事会第七次会议，审议通过了《关于使用部分闲置 募集资金进行现金管理的议案》，拟使用不超过人民币 20,000 万元的闲置募集 资金进行现金管理，该额度可滚动使用，自公司第五届董事会第七次会议审议通 过之日起十二个月内有效，并提请授权管理层行使决策权并签署相关合同文件， 具体事项由公司财务部负责组织实施。 一、募集资金基本情况 经中国证券监督管理委员会《关于核准广东丸美生物技术股份有限公司首次 公开发行股票的批复》（证监许可[2019]917 号）核准，并经上海证券交易所同 意，丸美生物首次公开发行人民币普通股（A 股）股票 4,100 万股，发行价格为 每股人民币 20.54 元。共计募集资金人民币 84,214.00 万 ...